BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, June 19, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

March 23, 2009

View Archived Issues

GABA receptor inverse agonist shows potential in in vivo models of Alzheimer's

Read More

ProteoTech reports on small molecule targeting alpha-synuclein aggregation for Parkinson's disease

Read More

MHRA accepts BioMarin's CTA for phase I/II clinical trial of BMN-110 in MPS IVA

Read More

Cryopyrin-associated periodic syndrome remission seen with canakinumab in phase III study

Read More

Valeant Pharmaceuticals International presents novel potassium channel modulators

Read More

Lipoxen and Glide collaborate to investigate delivery of SuliXen with Glide technology

Read More

Innocoll investigates CollaRx gentamicin surgical implant in phase III trial

Read More

Genzyme receives positive opinion for Renvela in patients with kidney disease

Read More

Glivec recommended for use in Europe in postsurgery gastrointestinal tumors

Read More

Qutenza receives positive CHMP recommendation for neuropathic pain

Read More

Alchemia and SDP enter drug discovery agreement for anticancer drugs targeting SK1

Read More

SciClone completes patient enrollment in phase II trial of pancreatic cancer drug RP-101

Read More

Starpharma completes patient testing in clinical trial of topical microbicide VivaGel

Read More

FDA issues letter to Oxygen outlining path forward to resume clinical studies of Oxycyte

Read More

Bristol-Myers Squibb withdraws marketing authorization application for Ixempra

Read More

FDA Advisory Committee supports rivaroxaban's favorable risk-benefit profile

Read More

Enzon initiates treatment of patients with survivin antagonist EZN-3042 under IND

Read More

Poniard to focus resources on oncology drug picoplatin

Read More

Sirion's sNDA for Durezol for uveitis is accepted for review by the FDA

Read More

Novel naphthalene derivatives patented by Servier

Read More

Pfizer reports on development, pharmacological profile of PF-2413873

Read More

Novel, orally bioavailable compound for the treatment of migraine presented by Merck

Read More

Novel cannabinoid 2 receptor agonists reported by Merck & Co.

Read More

Novel imidazopyrazine compounds discovered by BioFocus

Read More

Merck presents novel selective androgen receptor modulator

Read More

Characteristics of gamma-secretase inhibitor BMS-708163 detailed

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing